Research powered investment banking
Home
Research
Companies
Themes
Top Picks
Transactions
Events
Redeye
At a Glance
Our Culture
Investor Services
Corporate Broking
Corporate Finance
Newsroom
The Team
Careers
FAQ
Governance
Members network
Community
Posts
Investor Scoring
sign in
Member sign in
Join redeye
Home
research
Companies
Themes
Top Picks
Transactions
Events
redeye
About
At a Glance
Our Culture
Investor Services
Corporate Broking
Corporate Finance
Newsroom
The Team
Careers
FAQ
Governance
community
Posts
Investor Scoring
The latest from Redeye about Scandinavian Life Science and Technology companies
Episurf Medical
Hög aktivitet och ett nytt affärsområde
Addnode Group
Q2’19 Sales and EBITA 8% above forecast, 13% organic growth
Xbrane Biopharma
Ett bet på biosimilarer
Arise
I väntan på Skaftås-affären
BioArctic
Nya resultat tydliggör BAN2401’s unika profil
Beijer Electronics Group
Expecting a rebound
Mycronic
Ett blivande Large Cap-bolag
Enea
Starkt Q2'19 - även korrigerat för engångsposter
Orphazyme
Milestone reached in ALS
Alelion Energy Systems
High uncertainty, high potential
Northbaze/Jays Group
Sound of a turnaround
Q-linea
Trial preparations progressing well
Hansa Biopharma
Fortsätter planenligt
Events
07
Aug
ENLABS: Quarterly Report Presentation and Q&A (English)
20
Aug
Immunicum: Quarterly Report Presentation & Business Strategy Review (English)
21
Aug
IMINT: Live Quarterly Presentation and Q&A (Swedish)
28
Aug
Cancer Imaging Lunch
29
Aug
Investor Lunch
06
Sep
Mycronic: Investor Lunch
Announcements
New accounting principle to affect upcoming interim reports
Redeye söker Projektledare inom Corporate Finance
Redeye sponsrar integrationsprojektet Näringslivet Möter Förorten